Get it on Google Play

FDA grants Nuvation Bio fast track status for brain cancer drug

August 20, 2026 8:00 AM EDT Send to a Friend
Nuvation Bio Inc. (NYSE: NUVB) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to safusidenib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login